Dr. Tom Powles on NIAGARA: Perioperative Durvalumab Improves Overall Survival in MIBC

Thomas Powles, MBBS, MRCP, MD shares the groundbreaking results of the NIAGARA study, a global phase 3 trial involving 1,000 patients with muscle-invasive bladder cancer. Dr. Powles breaks down the trial’s design, including the addition of perioperative durvalumab to the standard chemotherapy and cystectomy regimen. The study revealed significant improvements in both event-free survival and overall survival, marking the first time immune therapy has shown a survival advantage in this patient population.